Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. (Q34222291)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. |
scientific article |
Statements
1 reference
Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. (English)
1 reference
Wei Luo
1 reference
Ying Meng
1 reference
Hong-Li Ji
1 reference
Chun-Qiu Pan
1 reference
Shan Huang
1 reference
Chang-Hui Yu
1 reference
Li-Ming Xiao
1 reference
Kai Cui
1 reference
Shu-Yuan Ni
1 reference
Zhen-Shu Zhang
1 reference
Xu Li
1 reference
30 March 2012
1 reference
1 reference
e34230
1 reference
30 March 2012
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference